Other Expense

Other expense consists of the following:



	Three Months Ended September 30,				Nine Months Ended September 30,
	2013		2014		2013		2014

Administrative consolidation costs	$	3,133	$	648	$	6,303	$	1,855
Costs associated with patent dispute, and other matters	1,475		39		2,211		3,233
Costs associated with shareholder activism	—		2,441		—		3,966
Costs associated with management restructuring	—		11,022		—		11,022
Costs associated with a business acquisition	—		334		—		444
Other expense	$	4,608	$	14,484	$	8,514	$	20,520

During 2013 and 2014, we restructured certain administrative functions. For the three and nine months ended September 30, 2013, we incurred $3.1 million and $6.3 million, respectively, in related costs and for the three and nine months ended September 30, 2014 we incurred $0.6 million and $1.9 million, respectively, in related costs consisting principally of severance charges.

During the three and nine months ended September 30, 2013, we incurred $1.5 million and $2.2 million, respectively, in legal costs associated with a patent infringement claim and for the three and nine months ended September 30, 2014, we incurred $0.0 million and $1.9 million, respectively, including $0.9 million in settlement costs during the first quarter of 2014 as further described in Note 12. In addition, the three and nine months ended September 30, 2014 also included $0.0 million and $1.3 million, respectively, in settlement costs and costs associated with a legal matter in which we prevailed at trial.

During the three and nine months ended September 30, 2014, we incurred $2.4 million and $4.0 million, respectively, in consulting and legal costs associated with shareholder activism.

During the three and nine months ended September 30, 2014, we incurred $11.0 million in costs associated with restructuring of executive management. These costs include severance payments, accelerated vesting of stock-based compensation awards, accrual of the present value of deferred compensation and other benefits to our then Chief Executive Officer as defined in his termination agreement; accelerated vesting of stock-based compensation awards to certain members of executive management and other benefits earned as further described in our Form 8-K filing on July 23, 2014.

During the third quarter of 2014, we purchased EndoDynamix, Inc. as further described in Note 16. During the three and nine months ended September 30, 2014, we incurred $0.3 million and $0.4 million, respectively, in costs associated with this purchase.